Here is the summary: Oncolytics Biotech develops pharmaceutical products for cancer treatment. Theyre developing pelareorep, an immunotherapeutic agent, in phase 3 trials for breast and pancreatic cancer. They have co-development agreements with Merck KGaA/Pfizer Inc. and Roche Holding AG. The company was founded in 1998 and is headquartered in Calgary, Canada.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.4 |